Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study

CNS Drugs
Nakao IwataTeruhiko Higuchi

Abstract

Blonanserin transdermal patch therapy is now available in Japan for the treatment of schizophrenia and may provide several advantages over the tablet formulation. The aim was to evaluate the long-term safety and efficacy of blonanserin transdermal patches in Japanese patients with schizophrenia. An open-label study was conducted in adults with schizophrenia at 37 sites in Japan. Patients were enrolled in either cohort 1 or 2. Patients in cohort 1 received 8-16 mg/day blonanserin tablets for 6 weeks and then 40-80 mg/day blonanserin patches for 52 weeks. The dose of blonanserin patches was determined according to the dose of the tablets. In cohort 2, every patient started from 40 mg/day and then 40-80 mg/day blonanserin transdermal patches for 52 weeks. Both cohorts had 1-2 weeks of follow-up. Safety endpoints included the incidence of adverse events (AEs), treatment-related AEs, extrapyramidal AEs [also assessed using the change in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) score], the use of any concomitant antiparkinsonian drugs, and skin-related AEs, including skin irritation. Patients also underwent assessment of laboratory values including for serum prolactin concentration, vital signs, body weight, electrocardiog...Continue Reading

References

Nov 1, 1991·Archives of General Psychiatry·W S Fenton, T H McGlashan
Jan 1, 1994·The Psychiatric Quarterly·J P LindenmayerS Grochowski
Jan 6, 2001·Neuron·D A Lewis, J A Lieberman
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Peter J WeidenJulie Locklear
Aug 10, 2007·The Journal of Clinical Psychiatry·Johannes HamannWerner Kissling
Jan 19, 2008·Journal of Behavioral Medicine·Karen S Ingersoll, Jessye Cohen
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Mar 6, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wolfgang GaebelEUFEST Study Group
Mar 24, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·René Ernst NielsenSten Levander
Aug 29, 2013·Therapeutic Advances in Psychopharmacology·Miriam Isaac, Carl Holvey
May 27, 2015·Human Psychopharmacology·Carlos De Las Cuevas, Wenceslao Peñate
Mar 28, 2018·Psychiatry and Clinical Neurosciences·Jun IshigookaYoshihiro Tadori
Jun 27, 2019·Neuropsychiatric Disease and Treatment·Giancarlo CerveriClaudio Mencacci

Citations

Related Concepts

Antiparkinson Agents
Asthma
Attitude
Pharmaceutical Preparations
Epistaxis
Fracture
Impulse Control Disorders
Laboratory
Laboratory Procedures
Nasopharyngitis

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.